217 related articles for article (PubMed ID: 26298540)
1. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment.
van de Bilt MT; Prado CM; Ojopi EP; Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF
Schizophr Res; 2015 Oct; 168(1-2):587-8. PubMed ID: 26298540
[TBL] [Abstract][Full Text] [Related]
2. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial.
Jürgens G; Andersen SE; Rasmussen HB; Werge T; Jensen HD; Kaas-Hansen BS; Nordentoft M
JAMA Netw Open; 2020 Dec; 3(12):e2027909. PubMed ID: 33284338
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
Naujokaitis D; Asmoniene V; Kadusevicius E
Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
Psychiatr Danub; 2010 Jun; 22(2):335-7. PubMed ID: 20562776
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
Dahl ML
Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
[TBL] [Abstract][Full Text] [Related]
6. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
[TBL] [Abstract][Full Text] [Related]
7. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
Dorado P; Peñas-Lledó EM; Llerena A
Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
[TBL] [Abstract][Full Text] [Related]
9. CYP 2D6 polymorphism and antipsychotic therapy.
Plesnicar BK; Dolzan V; Zalar B
Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
[TBL] [Abstract][Full Text] [Related]
10. The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study.
Kobylecki CJ; Hansen T; Timm S; Wang A; Jakobsen KD; Sørensen HJ; Rasmussen HB; Werge T
Ther Drug Monit; 2008 Jun; 30(3):265-70. PubMed ID: 18520596
[TBL] [Abstract][Full Text] [Related]
11. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics.
Austin-Zimmerman I; Wronska M; Wang B; Irizar H; Thygesen JH; Bhat A; Denaxas S; Fatemifar G; Finan C; Harju-Seppänen J; Giannakopoulou O; Kuchenbaecker K; Zartaloudi E; McQuillin A; Bramon E
Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828364
[TBL] [Abstract][Full Text] [Related]
12. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?
Herbild L; Andersen SE; Werge T; Rasmussen HB; Jürgens G
Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):266-72. PubMed ID: 23731498
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 and CYP2C19 genotyping in psychiatric patients on psychotropic medication in the former Dutch Antilles.
Koopmans AB; Vinkers DJ; Gelan PJ; Hoek HW; van Harten PN
Pharmacogenomics; 2017 Jul; 18(10):1003-1012. PubMed ID: 28639468
[TBL] [Abstract][Full Text] [Related]
14. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
[TBL] [Abstract][Full Text] [Related]
15. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 mutations and therapeutic outcome in schizophrenic patients.
Hamelin BA; Dorson PG; Pabis D; Still D; Bouchard RH; Pourcher E; Rail J; Turgeon J; Crismon ML
Pharmacotherapy; 1999 Sep; 19(9):1057-63. PubMed ID: 10610012
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry.
Kropp S; Lichtinghagen R; Winterstein K; Schlimme J; Schneider U
Clin Lab; 2006; 52(5-6):237-40. PubMed ID: 16812949
[TBL] [Abstract][Full Text] [Related]
18. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
[TBL] [Abstract][Full Text] [Related]
19. Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response.
Yadav SS; Ruwali M; Pant MC; Shukla P; Singh RL; Parmar D
Mutat Res; 2010 Feb; 684(1-2):49-55. PubMed ID: 19954746
[TBL] [Abstract][Full Text] [Related]
20. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.
Kohlrausch FB; Gama CS; Lobato MI; Belmonte-de-Abreu P; Callegari-Jacques SM; Gesteira A; Barros F; Carracedo A; Hutz MH
Pharmacogenet Genomics; 2008 Jul; 18(7):599-609. PubMed ID: 18551040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]